Type 2 Diabetes

Pipeline Assessment and Market Forecasts to 2017

Product Code GDA02029
Publication Date August 2010
Publisher GlobalData
Product Type Report
Pages 59
ISBN Number not applicable
Change currency
PDF £1,265.00 €1,523 $2,000 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Type 2 Diabetes

Pipeline Assessment and Market Forecasts to 2017

GlobalData, the industry analysis specialist, has released its new report, "Type 2 Diabetes - Pipeline Assessemnt and Market Forecasts to 2017". The report is an essential source of information and analysis on the global type 2 diabetes therapeutics market. The report identifies the key trends shaping and driving the global type 2 diabetes therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the market positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global type 2 diabetes sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimated the type 2 diabetes market to be worth $21.9 billion in 2009. The market is forecast to reach $36.1 billion by 2017 with a Compound Annual Growth Rate (CAGR) of 6% between 2010 and 2017. The main factors driving the growth of the market are the rapid growth in prevalence rates in the UK and the US, an increase in the utilization of premium priced drugs such as glitazones, an increase in prescriptions for combination drugs and an increase in the prevalence of obesity. Studies have found that obese people are three times more likely to be diagnosed with diabetes than normal people. The type 2 diabetes market has unmet needs in terms of safety and patient compliance. These unmet needs imply that the market is moderately served by the current treatment options and that significant potential exists for new entrants targeting these unmet needs.

GlobalData's analysis reveals that there are over 251 molecules in various stages of the pipeline. Victoza, one of the promising drugs, is awaiting the US Food and Drug Administration's (FDA) approval. The drug was approved by the European Medicines Agency (EMEA) in 2009. The late stage pipeline includes a few first-in-class and promising drugs such as dapagliflozin and D-Tagatose. These molecules differ from others as their site of action is different from that of the already marketed products. The major new classes of drugs include SGLT-2 inhibitors, 11ß HSD inhibitors, CCR2 antagonists, selective inhibitors of fructose 1,6-bisphosphatase, immune modulators, cortisol synthesis inhibitors, interleukin-1ß antagonists, Gastrin-Releasing Peptide (GRP) receptor agonists, GPR 119 agonists, TLR-4 receptor agonists, FXR antagonists and antisense drugs targeting glucagon receptors.

Scope

The scope of the report includes:

  • Annualized global type 2 diabetes therapeutics market revenue data from 2001 to 2009, forecast for eight years to 2017.
  • Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
  • Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include SGLT-2 inhibitors, 11ß HSD inhibitors, CCR2 antagonists, selective inhibitors of fructose 1,6-bisphosphatase, immune modulators, cortisol synthesis inhibitors, interleukin-1ß antagonists, Gastrin-Releasing Peptide (GRP) receptor agonists, GPR 119 agonists, TLR-4 receptor agonists, FXR antagonists and antisense drugs targeting glucagon receptors.
  • Analysis of the current and future market competition in the global type 2 diabetes therapeutics market. The key future market players covered are F. Hoffmann-La Roche, Novo Nordisk, Merck & Co., Novartis AG, Sanofi-aventis, Eli Lilly and Company and GlaxoSmithKline.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include a strategic competitor assessment, a market characterization, the unmet needs and the implications for the type-2 diabetes market

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global type 2 diabetes therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to affect the global type 2 diabetes therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidation, investments and strategic partnerships.
  • What's the next big thing in the global type 2 diabetes therapeutics market landscape? - Identify, understand and capitalize.

Contents

  • 1 Table of contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Diabetes Therapeutics Market: Introduction
    • 2.1 GlobalData Pipeline Report Guidance
  • 3 Type 2 Diabetes Therapeutics: Market Characterization
    • 3.1 Type 2 Diabetes Market Size
    • 3.2 Type 2 Diabetes Market Forecast and CAGR
    • 3.3 Drivers and Barriers for the Type 2 Diabetes Market
      • 3.3.1 Drivers for Type 2 Diabetes Market
      • 3.3.2 Restraints for Type 2 Diabetes Market
    • 3.4 Opportunity and Unmet Need
      • 3.4.1 Unmet Needs
      • 3.4.2 Impact Analysis of Unmet Needs
    • 3.5 Key Takeaway
  • 4 Type 2 Diabetes Therapeutics Market: Competitive Assessment
    • 4.1 Overview
    • 4.2 Strategic Competitor Assessment
    • 4.3 Product Profile for the Major Marketed Products in the Type 2 Diabetes Market
      • 4.3.1 Actos (pioglitazone)
      • 4.3.2 Avandia (rosiglitazone)
      • 4.3.3 Januvia (sitagliptin)
      • 4.3.4 Starlix (nateglinide)
      • 4.3.5 Byetta (exenatide)
      • 4.3.6 Lantus (insulin glargine)
      • 4.3.7 Levemir (insulin detemir)
    • 4.4 Key Takeaway
  • 5 Type 2 Diabetes Therapeutics Market: Pipeline Assessment
    • 5.1 Overview
    • 5.2 Strategic Pipeline Assessment
      • 5.2.1 Technology Trends Analytic Framework
    • 5.3 Type 2 Diabetes Therapeutics - Promising Drugs under Clinical Development
    • 5.4 Molecule Profile for Promising Drugs under Clinical Development
      • 5.4.1 BMS-512148 (dapagliflozin)
      • 5.4.2 Victoza
      • 5.4.3 D-Tagatose
      • 5.4.4 JNJ-28431754 (canagliflozin)
      • 5.4.5 MB07803
    • 5.5 Type 2 Diabetes Therapeutics Market-Clinical Pipeline by Mechanism of Action
    • 5.6 Type 2 Diabetes Pipeline-Pipeline by Phase of Clinical Development
      • 5.6.1 Type 2 Diabetes Therapeutics-Regulatory Filing and Phase III Clinical Pipeline
      • 5.6.2 Type 2 Diabetes Therapeutics - Phase II Clinical Pipeline
      • 5.6.3 Type 2 Diabetes Therapeutics - Phase I Clinical Pipeline
      • 5.6.4 Type 2 Diabetes Therapeutics - Preclinical Pipeline
      • 5.6.5 Type 2 Diabetes Therapeutics - Discovery Pipeline
    • 5.7 Discontinued / Suspended Drugs for Type 2 Diabetes
    • 5.8 Key Takeaway
  • 6 Type 2 Diabetes Therapeutics Market: Implications for Future Market Competition
  • 7 Type 2 Diabetes Therapeutics Market: Future Players in the Type 2 Diabetes Market
    • 7.1 Introduction
    • 7.2 GlaxoSmithKline
      • 7.2.1 Company Overview
      • 7.2.2 Business Description
      • 7.2.3 Type 2 Diabetes Therapeutics Portfolio
    • 7.3 Hoffmann-La Roche
      • 7.3.1 Company Overview
      • 7.3.2 Business Description
      • 7.3.3 Type 2 Diabetes Therapeutics Portfolio
    • 7.4 Novo Nordisk
      • 7.4.1 Overview
      • 7.4.2 Type 2 Diabetes Therapeutics Portfolio
    • 7.5 Merck & Co., Inc
      • 7.5.1 Overview
      • 7.5.2 Business Description
      • 7.5.3 Type 2 Diabetes Therapeutics Portfolio
    • 7.6 Novartis AG
      • 7.6.1 Company Overview
      • 7.6.2 Business Description
      • 7.6.3 Type 2 Diabetes Therapeutics Portfolio
    • 7.7 Sanofi-aventis
      • 7.7.1 Company Overview
      • 7.7.2 Business Description
      • 7.7.3 Type 2 Diabetes Therapeutics Portfolio
    • 7.8 Eli Lilly and Company
      • 7.8.1 Overview
      • 7.8.2 Type 2 Diabetes Therapeutics Portfolio
  • 8 Type 2 Diabetes Therapeutics Market: Appendix
    • 8.1 Definitions
    • 8.2 Scope of Pipeline Research
    • 8.3 Acronyms
    • 8.4 Research Methodology
      • 8.4.1 Coverage
      • 8.4.2 Secondary Research
      • 8.4.3 Forecasting
      • 8.4.4 Primary Research
      • 8.4.5 Expert Panel validation
    • 8.5 Contact Us
    • 8.6 Disclaimer
    • 8.7 Sources
  • 1.1 List of Tables
    • Table 1: Type 2 Diabetes Therapeutics, Global, Sales Value ($bn), 2001-2009
    • Table 2: Type 2 Diabetes Therapeutics, Global, Market Forecasts ($m), 2009-2017
    • Table 3: Type 2 Diabetes Market, Global, Most Promising Drugs Under Clinical Development, December 2010
    • Table 4: Type 2 Diabetes Therapeutics, Global, Regulatory Approval and Phase III Clinical Pipeline, 2010
    • Table 5: Type 2 Diabetes Therapeutics, Global, Phase II Clinical Development, 2010
    • Table 6: Type 2 Diabetes Therapeutics, Global, Phase I Clinical Development, 2010
    • Table 7: Type 2 Diabetes Therapeutics, Global, Preclinical Development, 2010
    • Table 8: Type 2 Diabetes Therapeutics, Global, Discovery Stage, 2010
    • Table 9: Type 2 Diabetes Therapeutics, Global, Discontinued drugs, 2010
    • Table 10: Type 2 Diabetes Therapeutics, Global, GlaxoSmithKline Products in the Market, 2010
    • Table 11: Type 2 Diabetes Therapeutics, Global, GlaxoSmithKline Pipeline Drugs, 2010
    • Table 12: Type 2 Diabetes Therapeutics, Global, Hoffmann-La Roche Pipeline Drugs, 2010
    • Table 13: Type 2 Diabetes Therapeutics, Global, Novo Nordisk Products in the Market, 2010
    • Table 14: Type 2 Diabetes Therapeutics, Global, Novo Nordisk Pipeline Drugs, 2010
    • Table 15: Type 2 Diabetes Therapeutics, Global, Merck & Co. Products in the Market, 2010
    • Table 16: Type 2 Diabetes Therapeutics, Global, Merck & Co. Pipeline Drugs, 2010
    • Table 17: Type 2 Diabetes Therapeutics, Global, Novartis Products in the Market, 2010
    • Table 18: Type 2 Diabetes Therapeutics, Global, Novartis Pipeline Drugs, 2010
    • Table 19: Type 2 Diabetes Therapeutics, Global, Sanofi-aventis Products in the Market, 2010
    • Table 20: Type 2 Diabetes Therapeutics, Global, Sanofi-aventis Pipeline Drugs, 2010
    • Table 21: Type 2 Diabetes Therapeutics, Global, Eli Lilly and Co. Products in the Market, 2010
    • Table 22: Type 2 Diabetes Therapeutics, Global, Eli Lilly & Co. Pipeline Drugs, 2010
  • 1.2 List of Figures
    • Figure 1: Type 2 Diabetes Therapeutics, Global, Sales Value ($bn), 2001-2009
    • Figure 2: Type 2 Diabetes Therapeutics, Global, Sales Value ($bn), 2009-2017
    • Figure 3: Type 2 Diabetes Therapeutics, Global, Market Opportunity and Unmet Needs, 2010
    • Figure 4: Type 2 Diabetes Therapeutics, Global, Strategic Competitor Assessment of Major Marketed Products, 2010
    • Figure 5: Type 2 Diabetes Therapeutics, Global, Pipeline, Technology Trends Analytic Framework, 2010
    • Figure 6: Type 2 Diabetes Therapeutics, Global, Pipeline, Description of Technology Trends Analytic Framework, 2010
    • Figure 7: Type 2 Diabetes Therapeutics Market-Clinical Pipeline by Mechanism of Action, 2010
    • Figure 8: Type 2 Diabetes Therapeutics, Global, Pipeline by Phase of Clinical Development, 2010
    • Figure 9: Implications for Future Market Competition in the Type 2 Diabetes Market, 2010
    • Figure 10: Type 2 Diabetes Therapeutics Market, Global, Clinical Pipeline by Company, 2010
    • Figure 11: GlobalData Methodology, 2010
    • Figure 12: GlobalData Market Forecasting Model, 2010